China Stroke Primary Prevention Trial for Subjects With H-type Hypertension and MTHFR 677 CC/CT Genotype

Hypertension Clinical Trial

— CSPPT2-CC/CT  

Official title:

Comparative Efficacy of Amlodipine Folic Acid vs. Amlodipine on the Risk of First Ischemic Stroke Among Patients With H-type Hypertension and MTHFR 677 CC/CT Genotype: A Multi-center, Randomized, Controlled Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04974138
• Other study ID #: CSPPT2-CC/CT_2020
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: April 1, 2022
• Est. completion date: April 30, 2027

Study information

• Verified date: March 2022
• Source: Shenzhen Ausa Pharmed Co.,Ltd
• Contact: Minqing Tian, PhD
• Phone: 86-18818680849
• Email: tianminqing[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, controlled, clinical trial stratified by participants with the MTHFR 677 genotype (CC and CT) in a 1:1 ratio. It aims to investigate the treatment effects of amlodipine folic acid vs. amlodipine on reducing the risk of first ischemic stroke among those participants with the MTHFR 677 CC/CT genotype and H-type hypertension (hypertension with increasing homocysteine (Hcy)).

This study consists of 3 phases: Screening, Run-in period (0 or 2 weeks), and randomized treatment (5 years), with a prospective, randomized, open-label, blinded end-point design.

Description:

This study consists of 3 phases: Screening, Run-in period, Randomized treatment.

Phase I: Screening (V0)

The purpose of phase I is to obtain informed consent and make a preliminary assessment of the patient.

At the first screening visit (V0), or prior to the official treatment visit, a clinical examination will be performed to determine the patient's clinical diagnosis and to determine eligibility for inclusion in the study. General demographic information will be obtained and questions related to the inclusion/exclusion criteria of this study will be asked. Additionally, this will be the time to discuss the impact of participant vacation/travel plans on adherence and compliance with the trial protocol.

Phase II: Run-in Period (VD)

Eligible patients who have not used antihypertensive drugs of Dihydropyridine Calcium Channel Blockers (CCBs) in the past two months, or who require further observation such as patients taking dihydropyridine CCBs but under the circumstances that may affect the evaluation of compliance and safety to patients like taking medicine irregularly, self-medication, and poor blood pressure control, will begin the treatment of amlodipine (5mg/d) for a 2-week run-in period. Those patients who have been taking antihypertensive drugs of dihydropyridine CCBs in the past two months and who report no adverse reactions, will skip the run-in period and directly begin the randomized treatment phase.

The primary purpose of this phase is to assess participant compliance for following the amlodipine treatment regimen as well as to observe the participant's tolerance to amlodipine, so as to avoid admitting those participants with poor compliance or an intolerance to amlodipine into the randomized treatment phase.

Phase III: Randomized Treatment (V1-V21)

The third phase consists of a 5-year period of randomized treatment. Patients who remain eligible for participation in the study will first be stratified by the MTHFR CC and CT genotype, for a total of 2 strata at the start of V1. Each stratum will then be randomized into 2 treatment groups: either amlodipine only tablets (5mg/d) or amlodipine folic acid tablets (5.8mg/d). During the 5-year randomized treatment period, other antihypertensive drugs can be combined with the treatment drug to achieve blood pressure control, including Candesartan (8mg/d) or/and Indapamide (1.5mg/d). Patients will be followed-up every 3 months during the treatment period, and the treatment drug will be distributed at each visit. During this period, participants should continue to avoid taking medications that may interfere with the evaluation of treatment efficacy.

After the Run-in Period, eligible participants, stratified by MTHFR CC/CT genotype and research centers, were randomly assigned, in a 1:1 ratio, to receive the two study treatments. Randomization was performed centrally by means of a computer-generated random-number sequence.

This study plans to enroll 25,000 participants. Based on the results of previous studies, the 5-year incidence of first ischemic stroke in people with hypertension without folic acid supplementation is about 3.0%. Assuming that the annual incidence of first ischemic stroke is 0.5%-0.6%, the enrollment of 25,000 patients will guarantee that a relative risk difference of 20% between the groups can be observed with more than 80% power at a two-sided significance level of α=0.05. For a 1% assumed annual incidence of first ischemic stroke, a relative risk difference of 15% between the groups with 80% or more power is assured.

For every 200 confirmed primary outcome events, an interim analysis will be conducted. This study anticipates conducting 4 interim analyses. The O'Brien-Fleming alpha-spending function will be used to define the significance level of each interim analysis to ensure that the final overall two-sided significance level of α=0.05 is met.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 25000
• Est. completion date: April 30, 2027
• Est. primary completion date: April 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Men and women, aged 50-75 years;

2. Previously diagnosed with primary hypertension and has been taking antihypertensive medication within the past two weeks, OR has not been taking antihypertensive medication within the last two weeks but meets the following criteria for hypertension: on two separate (not on the same day) visits in a clinical setting, blood pressure measurements (average of 3 measurements each time) showed SBP=140 mmHg and/or DBP=90 mmHg;

3. MTHFR 677 CC or CT genotype (based on test results from the central laboratory in the screening period or a previous official test report from the laboratory with medical testing qualifications);

4. Elevated homocysteine (=10 µmol/L);

5. Serum folate level <12 ng/mL;

6. Voluntarily participates and has given signed, informed consent.

Randomized-treatment phase inclusion criteria:

1. Good compliance during the run-in phase (assessed by a medical compliance survey for predicting patient compliance);

2. Tolerance of amlodipine besylate 5.0mg tablets (does not result in discontinuation of medication due to adverse effects);

3. No cardiovascular or cerebrovascular events occurred during the run-in phase;

4. Voluntarily agrees to continue with participation in the study.

Exclusion Criteria:

1. Previously diagnosed secondary hypertension;

2. Previously diagnosed stroke;

3. Previously diagnosed myocardial infarction;

4. Previously diagnosed heart failure;

5. Cardio-cerebral-kidney revascularization and/or other large arterial stenting;

6. Currently on dialysis, OR diagnosed with stage 4-5 chronic kidney disease, OR estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m²;

7. Known to have congenital (such as aortic stenosis) or acquired organic heart disease;

8. Known to have any of the following severe diseases or conditions:

a. Digestive system i. Previously diagnosed with any form of viral hepatitis that is currently still in the active phase; ii. Abnormal liver function test before enrollment (any of ALT, AST, GGT, TBIL, DBIL testing 3 times higher than normal, ALB = 30g/L); iii. Subtotal gastrectomy and/or gastrojejunostomy; b. Respiratory system i. Previously diagnosed with pulmonary heart disease and/or chronic obstructive pulmonary disease; c. Presence of malignant tumors or other severe diseases;

9. Participant, at the investigator's discretion, is assessed to be unsuitable for the study, for reasons including but not limited to the presence of abnormal laboratory results, or clinical abnormalities/signs;

10. Prior history of significant intolerance due to adverse reactions resulting from usage of amlodipine or other CCBs, candesartan or other ARBs, hydrochlorothiazide or other similar diuretics, or any drugs or health products containing folate or folic acid;

11. Regular consumption of folic acid or compounds containing folic acid in the past 3 months;

12. Presence of any of the following conditions that could negatively influence a participant's ability to consent or participate in the trial:

1. Dementia;

2. Severe mental disorders;

3. Inability to express informed consent;

4. Unlikely to complete the study follow-up as specified by the protocol, or plans to relocate outside of the study area in the near future;

5. History of poor compliance when taking antihypertensive medications or is expected to have poor compliance during the study;

13. Refusal to participate, or inability to modify current drug regimen;

14. Within one month of the first visit, participating in any clinical trial for any drug that has yet to be officially approved by the state and is not currently approved for sale, OR currently participating in any clinical trial that could potentially impact the results of this study (medication use, drug efficacy, drug interaction, etc.)

Related Conditions & MeSH terms

• Hypertension

Intervention

Drug:
• Amlodipine besylate tablets
The amlodipine used in this study is a listed product. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).
• Amlodipine besylate and folic acid tablets
The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. All drugs used in the Randomized Treatment Period of this study will be packed into bottles with the same outer appearance and corresponding labels of the clinical trial (100 tablets/bottle).

Locations

Country	Name	City	State
China	Peking University First Hospital	Beijing
China	First Affiliated Hospital of Harbin Medical University	Harbin
China	The First People's Hospital of Lianyungang	Lianyungang
China	Second Affiliated Hospital of Nanchang University	Nanchang
China	First Hospital of Shanxi Medical University	Taiyuan

Sponsors (7)

Lead Sponsor	Collaborator
Shenzhen Ausa Pharmed Co.,Ltd	First Affiliated Hospital of Harbin Medical University, Peking University First Hospital, Second Affiliated Hospital of Nanchang University, Shenzhen CCHRPP Biomedical Institute, The First Affiliated Hospital of Shanxi Medical University, The First People's Hospital of Lianyungang

Country where clinical trial is conducted

China, 

References & Publications (11)

Dong Q, Tang G, He M, Cai Y, Cai Y, Xing H, Sun L, Li J, Zhang Y, Fan F, Wang B, Sun N, Liu L, Xu X, Hou F, Shen H, Xu X, Huo Y. Methylenetetrahydrofolate reductase C677T polymorphism is associated with estimated glomerular filtration rate in hypertensive Chinese males. BMC Med Genet. 2012 Aug 16;13:74. — View Citation

Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr. 2005 Oct;82(4):806-12. — View Citation

Huang X, Li Y, Li P, Li J, Bao H, Zhang Y, Wang B, Sun N, Wang J, He M, Yin D, Tang G, Chen Y, Cui Y, Huang Y, Hou FF, Qin X, Huo Y, Cheng X. Association between percent decline in serum total homocysteine and risk of first stroke. Neurology. 2017 Nov 14;89(20):2101-2107. doi: 10.1212/WNL.0000000000004648. Epub 2017 Oct 13. — View Citation

Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, Tang G, Wang B, Chen D, He M, Fu J, Cai Y, Shi X, Zhang Y, Cui Y, Sun N, Li X, Cheng X, Wang J, Yang X, Yang T, Xiao C, Zhao G, Dong Q, Zhu D, Wang X, Ge J, Zhao L, Hu D, Liu L, Hou FF; CSPPT Investigator — View Citation

Kjeldsen SE, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press. 2001;10(4):190-2. Review. — View Citation

Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ. 1998 Mar 21;316(7135):894-8. — View Citation

Qin X, Li J, Cui Y, Liu Z, Zhao Z, Ge J, Guan D, Hu J, Wang Y, Zhang F, Xu X, Wang X, Xu X, Huo Y. Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetrahydrofolate reductase and methionine — View Citation

Qin X, Li J, Cui Y, Liu Z, Zhao Z, Ge J, Guan D, Hu J, Wang Y, Zhang F, Xu X, Wang X, Xu X, Huo Y. MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults. Nutr J. 201 — View Citation

Qin X, Li J, Zhang Y, Ma W, Fan F, Wang B, Xing H, Tang G, Wang X, Xu X, Xu X, Huo Y. Prevalence and associated factors of diabetes and impaired fasting glucose in Chinese hypertensive adults aged 45 to 75 years. PLoS One. 2012;7(8):e42538. doi: 10.1371/j — View Citation

Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M, Stoll C, Alembik Y, Dott B, Czeizel AE, Gelman-Kohan Z, Scarano G, Bianca S, Ettore G, Tenconi R, Bellato S, Scala I, Mutchinick OM, López MA, de Walle H, Hofstra R, Joutchenko L, Kavteladze L, Bermejo E, Martínez-Frías ML, Gallagher M, Erickson JD, Vollset SE, Mastroiacovo P, Andria G, Botto LD. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet. 2003 Aug;40(8):619-25. Erratum in: J Med Genet. 2004 May;41(5):400. Redlund, M [corrected to Renlund, M]. — View Citation

Xu X, Li J, Sheng W, Liu L. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis. 2008;26(1):48-62. doi: 10.1159/000135653. Epub 2008 May 30. — View Citation

* Note: There are 11 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of malignant tumors	This study investigates the treatment effects of amlodipine folic acid (5.8 mg/d) compared to amlodipine besylate (5.0 mg/d) on the risk of developing malignant tumors.	By the end of the fifth year from baseline
Other	Measurement of Carotid Intima Media Thickness (CIMT)	This study investigates the treatment effects of amlodipine folic acid (5.8 mg/d) compared to amlodipine besylate (5.0 mg/d) on Carotid Intima Media Thickness (CIMT).	By the end of the fifth year from baseline
Other	Measurement of brachial-ankle Pulse Wave Velocity (baPWV)	This study investigates the effects of amlodipine folic acid (5.8 mg/d) compared to amlodipine besylate (5.0 mg/d) on Brachial-ankle Pulse Wave Velocity (baPWV).	By the end of the fifth year from baseline
Primary	First ischemic stroke	This study investigates whether, among patients with H-type hypertension and the MTHFR 677 CC or CT genotype, there is a statistically significant difference in treatment efficacy between amlodipine folic acid (5.8 mg/d) and amlodipine besylate (5.0 mg/d) for the prevention of first ischemic stroke.; The risk (hazard ratio) and time of the event of first ischemic stroke will be measured by Kaplan-Meier survival analyses, log-rank tests, and Cox proportional-hazards regression models at the significance level of a=0.05 (two-sided test).	By the end of the fifth year from baseline
Secondary	Cardiovascular related events	This study investigates the treatment effects of amlodipine folic acid (5.8 mg/d) compared to amlodipine besylate (5.0 mg/d) on the following six endpoints: combined cardiovascular endpoints (first stroke, first hospitalization from myocardial infarction, first hospitalization from heart failure, or cardiovascular death), first stroke (ischemic or hemorrhagic stroke), first hospitalization due to myocardial infarction, first hospitalization due to heart failure, cardiovascular death, and all-cause death.; The risk and time of event of any secondary endpoints will be measured by Kaplan-Meier survival analyses, log-rank tests, and Cox proportional-hazards regression models at the significance level of a=0.05 (two-sided test).	By the end of the fifth year from baseline
Secondary	Effect modification of the MTHFR 677 genotype on cardiovascular events	This study investigates the effect modification of the MTHFR 677 genotype (CC or CT) on the treatment efficacy of amlodipine folic acid on secondary endpoints, compared to amlodipine besylate.; Stratified by the MTHFR 677 genotype (CC or CT), the risk and time of event of any secondary endpoints in each group will be measured by Kaplan-Meier survival analyses, log-rank tests, and Cox proportional-hazards regression models at the significance level of a=0.05 (two-sided test).	By the end of the fifth year from baseline
Secondary	Amlodipine-based multi-antihypertensive drug combinations on cardiovascular events	This study investigates whether, among patients with H-type hypertension and the MTHFR 677 CC/CT genotype who require a multi-drug antihypertensive regimen, there is a statistically significant difference among the combinations of two multi-antihypertensive drugs on each of the following 7 endpoints: first stroke, first ischemic stroke, first hemorrhagic stroke, first hospitalization due to myocardial infarction, first hospitalization due to heart failure, cardiovascular death, and all-cause death.; Stratified by different amlodipine-based multi-antihypertensive drug combinations, the risk and time of event of any secondary endpoints in each group will be measured by Kaplan-Meier survival analyses, log-rank tests, and Cox proportional-hazards regression models at the significance level of a=0.05 (two-sided test).	By the end of the fifth year from baseline